In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...

The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...

New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...

RSV prevention among children, including nirsevimab and the maternal RSVpreF vaccine, may be associated with a reduction in pediatric ICU utilization.

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute ...

Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...

The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...

A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...

RSV cases, hospitalisations and ICU admissions notified in 12 weeks to mid-November were between six and seven times lower ...

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

RSV is the most common cause of hospitalization in infants under 1 year old. The infection can spread to the lungs and cause ...

Nirsevimab is also recommended for some younger children between ages 8 and 19 months, particularly those who are at an increased risk for RSV. The CDC recommends all adults ages 75 and older and ...